arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2023-29-2-231-240arthyper-2323Research ArticleСтатьиArticlesИнгибитор ангиотензинпревращающего фермента, антагонист кальция и диуретик — три ведущих компонента терапии в лечении артериальной гипертензии. Какие преимущества может дать тройная фиксированная комбинация?ACE-inhibitor, calcium antagonist and diuretic as three major components of antihypertensive therapy. Potential advantages of fixed triple combinationshttps://orcid.org/0000-0001-8169-7812КонрадиА. О.KonradiA. O.

Конради Александра Олеговна — доктор медицинских наук, профессор, академик Российской академии наук, заведующая кафедрой организации, управления и экономики здравоохранения Института медицинского образования, заместитель генерального директора по научной работе ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России.

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Тел.: 8 (812) 702-37-33

Aleksandra O. Konradi - MD, PhD, DSc, Professor, Academician of the Russian Academy of Sciences, Head, the Department of Organization, Management and Economics of Healthcare of the Institute of Medical Education, Deputy Director General for Scientific Work, Almazov National Medical Research Centre.

2 Akkuratov str., St Petersburg, 197341

Phone: 8(812)702-37-33

konradi@almazovcentre.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CenterRussian Federation202314052023292231240Copyright © Конради А.О., 20232023Конради А.О.Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2323

Статья описывает текущую ситуацию в мире и в России в отношении информированности пациентов о наличии у них артериальной гипертензии и приверженности к лечению. Рассматривается роль тройных фиксированных комбинаций, в частности комбинации амлодипина, индапамида и периндоприла, для повышения комплаентности пациентов и улучшения прогноза.

The article describes the current situation in hypertension awareness and treatment, the role of treatment adherence and fixed-dose combinations in its improvement. The real world data form recent studies concerning adherence and outcome on the triple combination of amlodipine/indapamide/perindopril are demonstrated.

артериальная гипертензияфиксированные комбинации препаратовамлодипининдапамидпериндоприлhypertensionfixed combinationsamlodipineperindoprilindapamideСтатья подготовлена при информационной поддержке компании «Сервье» (Франция), что никоим образом не повлияло на мнение автора и материал статьи.The article was prepared with the informational support of the Servier company (France), which in no way affected the opinion of the author and the presented data.ReferencesGBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786Arterial hypertension in adults. Clinical guidelines 2020. Rossijskij Kardiologicheskij Zhurnal = Russian Journal of Cardiology. 2020; 25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429. doi:10.1093/eurheartj/ehab484Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429. doi:10.1093/eurheartj/ehab484Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д., Артамонова Г. В., Гатагонова Т. М. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4): 4-14. doi:10.15829/1728-8800-2014-4-4-14Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14. In Russian.Баланова Ю. А., Шальнова С. А., Имаева А. Э., Капустина А. В., Муромцева Г. А., Евстифеева С. Е. и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019;15(4):450-466. doi:10.20996/1819-6446-2019-15-4-450-466Balanova YuA, Shalnova SA, Imaeva AE, Kapustina AV, Muromtseva GA, Evstifeeva SV et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (data of observational ESSERF-2 study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-466. doi:10.20996/1819-6446-2019-15-4-450-466. In Russian.Баланова Ю. А., Шальнова С. А., Куценко В. А., Имаева А. Э., Капустина А. В., Муромцева Г. А. и др. Вклад артериальной гипертонии и других факторов риска в выживаемость и смертность в российской популяции. Кардиоваскулярная терапия и профилактика. 2021;20(5):3003. doi:10.15829/1728-8800-2021-3003Balanova YuA, Shalnova SA, Kutsenko VA, Imaeva AE, Kapustina AV, Muromtseva GA et al. Contribution of hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. In Russian.Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al.; MMM Investigators. May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020;76(2): 333-341. doi:10.1161/HYPERTENSIONAHA.120.14874Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al.; MMM Investigators. May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020;76(2): 333-341. doi:10.1161/HYPERTENSIONAHA.120.14874Rotar OP, Konradi AO, Tanicheva AA, Nakonechnikov SN, Blinova NV, Beaney T et al. May Measurement Month 2017 in Russia: hypertension treatment and control-Europe. Eur Heart J Suppl. 2019;21(Suppl D): D 101-D 103. doi:10.1093/eurheartj/suz068Rotar OP, Konradi AO, Tanicheva AA, Nakonechnikov SN, Blinova NV, Beaney T et al. May Measurement Month 2017 in Russia: hypertension treatment and control-Europe. Eur Heart J Suppl. 2019;21(Suppl D): D 101-D 103. doi:10.1093/eurheartj/suz068Ротарь О. П., Толкунова К. М., Солнцев В. Н., Ерина А. М., Бояринова М. А., Алиева А. С. и др. Приверженность к лечению и контроль артериальной гипертензии в рамках российской акции скрининга МММ19. Российский кардиологический журнал. 2020;25(3):3745. doi:10.15829/1560-4071-2020-3-3745Rotar OP, Tolkunova KM, Solntsev VN, Erina AM, Boyarinova MA, Alieva AS et al. May Measurement Month 2019: adherence to treatment and hypertension control in Russia. Russian Journal of Cardiology. 2020;25(3):3745. doi:10.15829/1560-4071-2020-3-3745. In Russian.Ротарь О. П., Ерина А. М., Бояринова М. А., Могучая Е. В., Колесова Е. П., Толкунова К. М. и др. Контроль артериальной гипертензии в период пандемии коронавирусной инфекции: результаты российской акции скрининга МММ2021. Российский кардиологический журнал. 2022;27(4):5014. doi:10.15829/1560-4071-2022-5014Rotar OP, Erina AM, Boiarinova MA, Moguchaia EV, Kolesova EP, Tolkunova KM et al. Hypertension control during the COVID-19 pandemic: results of the MMM2021 in Russia. Russian Journal of Cardiology. 2022;27(4):5014. doi:10.15829/1560-4071-2022-5014. In Russian.Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ et al.; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-1425. doi:10.1016/S0140-6736(22)01786-XMackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ et al.; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-1425. doi:10.1016/S0140-6736(22)01786-XYang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: A Population-Based Cohort Study. J Am Heart Assoc. 2017;6(6):e006056. doi:10.1161/JAHA.117.006056Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: A Population-Based Cohort Study. J Am Heart Assoc. 2017;6(6):e006056. doi:10.1161/JAHA.117.006056Paz MA, de-La-SierraA, Saez M, Barcelo MA, Rodriguez JJ, Castro S et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore). 2016;95(30):e4071. doi:10.1097/MD.0000000000004071Paz MA, de-La-SierraA, Saez M, Barcelo MA, Rodriguez JJ, Castro S et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore). 2016;95(30):e4071. doi:10.1097/MD.0000000000004071Del Pinto R, Desideri G, Ferri C, Agabiti Rosei E. Realworld antihypertensive treatment patterns, treatment adherence, and blood pressure control in the elderly: An Italian Awareness-raising Campaign on Hypertension by Senior Italia Feder Anziani, the Italian Society of Hypertension and the Italian Federation of General Practitioners. High Blood Press Cardiovasc Prev. 2021;28(5):457-466. doi:10.1007/s40292-021-00465-7Del Pinto R, Desideri G, Ferri C, Agabiti Rosei E. Realworld antihypertensive treatment patterns, treatment adherence, and blood pressure control in the elderly: An Italian Awareness-raising Campaign on Hypertension by Senior Italia Feder Anziani, the Italian Society of Hypertension and the Italian Federation of General Practitioners. High Blood Press Cardiovasc Prev. 2021;28(5):457-466. doi:10.1007/s40292-021-00465-7WHO expert committee on the 2019 selection and use of essential medicines, the selection and use of essential medicines. 2019.WHO expert committee on the 2019 selection and use of essential medicines, the selection and use of essential medicines. 2019.Syed YY. Perindopril/indapamide/amlodipine in hypertension: a profile of its use. Am J Cardiovasc Drugs. 2022;22(2):219-230. doi:10.1007/s40256-022-00521-0Syed YY. Perindopril/indapamide/amlodipine in hyper-tension: a profile of its use. Am J Cardiovasc Drugs. 2022;22(2):219-230. doi:10.1007/s40256-022-00521-0Nedogoda SV, Stojanov VJ. Single-pill combination of perindopril/indapamide/amlodipine in patients with uncontrolled hypertension: A Randomized Controlled Trial. Cardiol Ther. 2017;6(1):91-104. doi:10.1007/s40119-017-0085-7Nedogoda SV, Stojanov VJ. Single-pill combination of perindopril/indapamide/amlodipine in patients with uncontrolled hypertension: A Randomized Controlled Trial. Cardiol Ther. 2017;6(1):91-104. doi:10.1007/s40119-017-0085-7Sarzani R, Giulietti F, Filipponi A, Marziali S, Ristori L, Buscarini S et al. The number of pills, rather than the type of renin-angiotensin system inhibitor, predicts ambulatory blood pressure control in essential hypertensives on triple therapy: A Real-Life Cross-Sectional Study. Adv Ther. 2021;38(7):4013-4025. doi:10.1007/s12325-021-01799-3Sarzani R, Giulietti F, Filipponi A, Marziali S, Ristori L, Buscarini S et al. The number of pills, rather than the type of renin-angiotensin system inhibitor, predicts ambulatory blood pressure control in essential hypertensives on triple therapy: A Real-Life Cross-Sectional Study. Adv Ther. 2021;38(7):4013-4025. doi:10.1007/s12325-021-01799-3Borghi C, Wang J, Rodionov AV, Rosas M, Sohn IS, Alcocer L et al. Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. Int J Cardiol Cardiovasc Risk Prev. 2021;10:200102. doi:10.1016/j.ijcrp.2021.200102Borghi C, Wang J, Rodionov AV, Rosas M, Sohn IS, Alcocer L et al. Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. Int J Cardiol Cardiovasc Risk Prev. 2021;10:200102. doi:10.1016/j.ijcrp.2021.200102Dusing R, Waeber B, Destro M, Santos Maia C, Brunel P Triple-combination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017;31(8):501-510. doi:10.1038/jhh.2017.5Dusing R, Waeber B, Destro M, Santos Maia C, Brunel P Triple-combination therapy in the treatment of hypertension: a re-view of the evidence. J Hum Hypertens. 2017;31(8):501-510. doi:10.1038/jhh.2017.5Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and adherence to treatment with perindopril/ indapamide/amlodipine single-pill combination in a Greek population with hypertension. Clin Drug Investig. 2019;39(4):385-393. doi:10.1007/s40261-019-00761-0Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and adherence to treatment with perindopril/ indapamide/amlodipine single-pill combination in a Greek population with hypertension. Clin Drug Investig. 2019;39(4):385-393. doi:10.1007/s40261-019-00761-0Kim SJ, Kwon OD, Cho B, Oh SW, Lee CM, Choi HC. Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study. BMJ Open. 2019;9(6):e029862. doi:10.1136/bmjopen-2019-029862Kim SJ, Kwon OD, Cho B, Oh SW, Lee CM, Choi HC. Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study. BMJ Open. 2019;9(6):e029862. doi:10.1136/bmjopen-2019-029862Putignano D, Orlando V, Monetti VM, Piccinocchi G, Musazzi UM, Piccinocchi R et al. Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy. Patient Prefer Adherence. 2019;13:1961-1969. doi:10.2147/PPA.S225444Putignano D, Orlando V, Monetti VM, Piccinocchi G, Musazzi UM, Piccinocchi R et al. Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy. Patient Prefer Adherence. 2019;13:1961-1969. doi:10.2147/PPA.S225444Карпов Ю. А., Горбунов В. М., Логунова Н. А. Применение тройной фиксированной комбинации в лечении артериальной гипертензии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования ТРИКОЛОР. Российский кардиологический журнал. 2020;25(10):4130. doi:10.15829/1560-4071-2020-4130Karpov YuA, Gorbunov VM, Logunova NA. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020;25(10):4130. doi:10.15829/1560-4071-2020-4130. In Russian.Cicero AFG, Fogacci F, Rizzoli E, D'Addato S, Borghi C. Long-term impact of different triple combination antihypertensive medications on blood pressure control, metabolic pattern and incident events: data from the Brisighella Heart Study. J Clin Med. 2021;10(24):5921. doi:10.3390/jcm10245921Cicero AFG, Fogacci F, Rizzoli E, D'Addato S, Borghi C. Long-term impact of different triple combination antihypertensive medications on blood pressure control, metabolic pattern and incident events: data from the Brisighella Heart Study. J Clin Med. 2021;10(24):5921. doi:10.3390/jcm10245921Borghi C, Jayagopal PB, Konradi AO, Bortolotto LA, Degli Esposti L, Perrone V et al. Adherence to triple single-pill combination of perindopril/indapamide/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023;40(4):1765-1772. doi:10.1007/s12325-023-02451-yBorghi C, Jayagopal PB, Konradi AO, Bortolotto LA, Degli Esposti L, Perrone V et al. Adherence to triple single-pill combination of perindopril/indapamide/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023;40(4):1765-1772. doi:10.1007/s12325-023-02451-yBorghi C, Jayagopal PB, Konradi AO et al. A real-world analysis of pharmaco-utilization and outcomes of patients on perindopril/amlodipine/indapamide free vs single-pill combination in Italy. Abstracts of the 29th Scientific Meeting of the International Society of Hypertension, 2022.Borghi C, Jayagopal PB, Konradi AO et al. A real-world analysis of pharmaco-utilization and outcomes of patients on perindopril/amlodipine/indapamide free vs single-pill combination in Italy. Abstracts of the 29th Scientific Meeting of the International Society of Hypertension, 2022.

The authors declare that there are no conflicts of interest present.